Dr. Reddy's Laboratories announces the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).

The Quelicin® brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*.

Dr. Reddy's Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), is available in multi-dose vials.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4826.75 as compared to the previous close of Rs. 4886.85. The total number of shares traded during the day was 58440 in over 6070 trades.

The stock hit an intraday high of Rs. 4923.8 and intraday low of 4806.45. The net turnover during the day was Rs. 285050830.

Source : Equity Bulls

Keywords